ADC Therapeutics (ADCT) Free Cash Flow: 2019-2023
Historic Free Cash Flow for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2023 value amounting to -$32.0 million.
- ADC Therapeutics' Free Cash Flow rose 76.88% to -$32.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$121.9 million, marking a year-over-year increase of 11.86%. This contributed to the annual value of -$124.7 million for FY2024, which is 2.30% down from last year.
- Per ADC Therapeutics' latest filing, its Free Cash Flow stood at -$32.0 million for Q4 2023, which was up 14.39% from -$37.3 million recorded in Q3 2023.
- In the past 5 years, ADC Therapeutics' Free Cash Flow registered a high of $2,195 during Q3 2022, and its lowest value of -$233.2 million during Q4 2021.
- For the 3-year period, ADC Therapeutics' Free Cash Flow averaged around -$41.1 million, with its median value being -$8.2 million (2021).
- Its Free Cash Flow has fluctuated over the past 5 years, first soared by 103.75% in 2022, then crashed by 1,700,965.60% in 2023.
- Over the past 5 years, ADC Therapeutics' Free Cash Flow (Quarterly) stood at -$122.3 million in 2019, then reached -$32.5 million in 2020, then spiked by 99.83% to -$233.2 million in 2021, then spiked by 40.73% to -$138.2 million in 2022, then skyrocketed by 76.88% to -$32.0 million in 2023.
- Its Free Cash Flow was -$32.0 million in Q4 2023, compared to -$37.3 million in Q3 2023 and -$36.2 million in Q2 2023.